Lay summary
Seven derivatives of vascular targeting antibodies developed in the Group Neri (four immunocytokines and three radiolabeled antibodies) are currently being investigated in Phase I and Phase II clinical trials, in collaboration with pharmaceutical companies. In order to capitalize on the experience gained over the last thirteen years of research in vascular tumor targeting, within the frame of this SNF Grant we have mainly focused on: (i) the isolation of novel human monoclonal antibodies specific to newly identified putative markers of angiogenesis (ii) the development and in vivo testing of novel vascular targeting immunocytokines, alone and in combination with other drugs, for applications in oncology or in other angiogenesis-related diseases.